BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Erman A, Krahn MD, Hansen T, Wong J, Bielecki JM, Feld JJ, Wong WWL, Grootendorst P, Thein HH. Estimation of fibrosis progression rates for chronic hepatitis C: a systematic review and meta-analysis update. BMJ Open 2019;9:e027491. [PMID: 31719068 DOI: 10.1136/bmjopen-2018-027491] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Abdelkader RY, Abdelrazek MA, Attallah A, Farid K, El-Far M. High blood glucose levels are associated with fibrosis/cirrhosis progression in chronic hepatitis C. J Immunoassay Immunochem 2021;:1-12. [PMID: 33886414 DOI: 10.1080/15321819.2021.1911813] [Reference Citation Analysis]
2 Kim KA, Choi GH, Jang ES, Kim YS, Lee YJ, Kim IH, Cho SB, Ki M, Choi HY, Paik D, Jeong SH. Epidemiology and treatment status of hepatitis C virus infection among people who have ever injected drugs in Korea: a prospective multicenter cohort study from 2007 to 2019 in comparison with non-PWID. Epidemiol Health 2021;43:e2021077. [PMID: 34645207 DOI: 10.4178/epih.e2021077] [Reference Citation Analysis]
3 Kouroumalis E, Voumvouraki A. Hepatitis C virus: A critical approach to who really needs treatment. World J Hepatol 2022; 14(1): 1-44 [DOI: 10.4254/wjh.v14.i1.1] [Reference Citation Analysis]
4 Mendlowitz AB, Naimark D, Wong WWL, Capraru C, Feld JJ, Isaranuwatchai W, Krahn M. The emergency department as a setting-specific opportunity for population-based hepatitis C screening: An economic evaluation. Liver Int. 2020;40:1282-1291. [PMID: 32267604 DOI: 10.1111/liv.14458] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Mendlowitz A, Bremner KE, Walker JD, Wong WWL, Feld JJ, Sander B, Jones L, Isaranuwatchai W, Krahn M. Health care costs associated with hepatitis C virus infection in First Nations populations in Ontario: a retrospective matched cohort study. CMAJ Open 2021;9:E897-906. [PMID: 34584004 DOI: 10.9778/cmajo.20200247] [Reference Citation Analysis]
6 Skladaný L, Oltman M, Fraňková S, Dražilová S, Husa P, Šperl J, Hejda V, Urbánek P, Adamcová-Selčanová S, Janičko M, Kristian P, Kupčová V, Rác M, Schréter I, Virág L, Liptáková A, Ondrášová M, Jarčuška P. Chronic hepatitis C virus infection in the Czech Republic and Slovakia: an analysis of patient and virus characteristics. Int J Public Health 2020;65:1723-35. [PMID: 33040165 DOI: 10.1007/s00038-020-01496-y] [Reference Citation Analysis]
7 Koo V, Tian F, Wong WWL. Cost-effectiveness analysis of hepatitis C virus (HCV) point-of-care assay for HCV screening. Liver Int 2021. [PMID: 34847288 DOI: 10.1111/liv.15123] [Reference Citation Analysis]
8 Zhou HJ, Cao J, Shi H, Naidoo N, Semba S, Wang P, Fan YF, Zhu SC. Cost-Effectiveness Analysis of Pan-Genotypic Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C Genotype 1 Infection in China. Front Public Health 2021;9:779215. [DOI: 10.3389/fpubh.2021.779215] [Reference Citation Analysis]
9 Greenaway E, Haines A, Ling SC, Krahn M. Treatment of Chronic Hepatitis C in Young Children Reduces Adverse Outcomes and Is Cost-Effective Compared to Deferring Treatment to Adulthood. J Pediatr. 2020;. [PMID: 32890583 DOI: 10.1016/j.jpeds.2020.08.088] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
10 Magri MC, Alvarez MSM, Iogi AA, Alves GM, Manchiero C, Dantas BP, Prata TVG, Nunes AKDS, Tengan FM. Study of CXCL9-11 gene polymorphisms in liver fibrosis among patients with chronic hepatitis C. Pathog Dis 2021;79:ftab007. [PMID: 33476381 DOI: 10.1093/femspd/ftab007] [Cited by in F6Publishing: 1] [Reference Citation Analysis]